This is to inform that due to some circumstances beyond the organizer control, "3rd Edition of International Precision Medicine Conference" (IPMC 2023) scheduled during April 24-26, 2023 in Orlando, Florida, USA has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at precision-medicine@magnusconference.com or call + 1 (702) 988 2320.
Pharmacometabolomics is a subset of metabolomics, which is the science of quantifying and analyzing the metabolites found in biological samples. Pharmacometabolomics, which is rapidly gaining popularity, has already started to blossom in the sectors of drug development and personalised medicine, where it is already assisting in the development of major insights and the advancement of knowledge and product offerings in these fields. Pharmacometabolomics is a subset of metabolomics that focuses on analyzing metabolites to determine how individuals respond to therapy. Pharmacometabolomics can assist in identifying individuals or groups of persons who are most likely to respond to treatments. It can also help to identify those who are at risk of experiencing adverse side effects
Title : Copper (II) complexes as potential anticancer agents
Salah S Massoud, University of Louisiana, United States
Title : Leveraging blockchain technology, edge computing and federated learning to enhance outcomes in precision medicine
Ingrid Vasiliu Feltes, MEDNAX, United States
Title : The new horizons in the patient- centered care for understanding of the reasons of its health problems – Psychosynthesis approach
Ewa Danuta Bialek, Institute of Psychosynthesis, Poland
Title : Hegazy theory for interpretation of human parthenogenesis: A new hypothesis
Abdelmonem Awad Hegazy, Zagazig University, Egypt
Title : Precision Oncology and Personalised Medicine: Innovative Technology for the Treatment of Colorectal Cancer
Huiqin Yang, ICON Clinical Research Ltd, United Kingdom
Title : The role of CD44v6 as a new immunotherapy target for urothelial cancer
Iris Adriana Maria Lodewijk, Institute of Biomedical Research, Spain